Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment.
Department of Microbiology & Immunology, Brody School of Medicine, East Carolina University, 600 Moye Blvd., Greenville, NC 27834, USA.
William H
WH
Chappell
Stephen L
SL
Abrams
Kristin M
KM
Stadelman
Michelle M
MM
LaHair
Richard A
RA
Franklin
Lucio
L
Cocco
Camilla
C
Evangelisti
Francesca
F
Chiarini
Alberto M
AM
Martelli
Linda S
LS
Steelman
James A
JA
McCubrey
D000209:Acute-Phase Proteins / Q000819:agonists / Q000235:genetics* / Q000378:metabolism; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D020128:Inhibitory Concentration 50; D000071068:Lipocalin-2; D054834:Lipocalins / Q000819:agonists / Q000235:genetics* / Q000378:metabolism; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000235:genetics* / Q000378:metabolism; D017239:Paclitaxel / Q000494:pharmacology*; D011518:Proto-Oncogene Proteins / Q000819:agonists / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
D000209:Acute-Phase Proteins; D000903:Antibiotics, Antineoplastic; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins; D004317:Doxorubicin; D020780:Matrix Metalloproteinase 9; D017239:Paclitaxel